The role of GR in supporting the growth of castration-resistant prostate cancer was further demonstrated by Puhr and colleagues, showing that GR expression is upregulated in metastatic lesions and significantly increased upon long-term abiraterone or enzalutamide (ENZA) treatment (12). This evidence concerns the gene NR3C1 and prostate carcinoma.